Corporate Profile


We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

By leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Two royalty bearing collaborations with AbbVie and Boehringer Ingelheim.

Two innovative clinical programs: NATIVE and IMPROVES.

Pre-clinical pipeline in oncology and fibrosis.

State-of-the-art R&D capabilities inherited from Abbott, Solvay, Fournier.

Financial Information


Upcoming Events

Q3 financial information -Revenues and cash

12th November 2020
(after market)

Q4 financial information -Revenues and cash

13th February 2021 2021
(after market)

Share Information

€10.02 -1.18%

Last update: Sep 18, 2020 at 17:35 CET


Open: €10.12
Previous close: €10.14

Day High: €10.14
Day Low: €9.9

Governance


Inventiva was co-founded by Frédéric Cren, Chairman, CEO and Co-Founder and Pierre Broqua, Chief Scientific Officer in Dijon in 2012.

Both have strong expertise within the areas of research, development and strategy and held senior research and executive positions at both Fournier and Solvay prior to founding Inventiva.

Investor Contacts


Inventiva
50 rue de Dijon
21121 Daix, France
Email: finance@inventivapharma.com
Tel: +33 (0)3 80 44 75 00

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com